RxDoctor Payments Data

John Harvey, MD

Internal Medicine · San Angelo, TXNPI 1811952427

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 66 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$192
  • Pfizer$180
  • Novartis$119
  • Merck$104
  • Lilly USA, LLC$90
  • Boehringer Ingelheim$67
  • plus $437 from 15 others

What the payments were for

  • Food & beverage$1,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,190 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$254,365
Medicare patients
576
Services billed
3,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$122,366
EliquisApixaban160$121,593
OzempicSemaglutide106$105,862
MounjaroTirzepatide52$56,793
XareltoRivaroxaban32$43,261
Tresiba Flextouch U-200Insulin Degludec19$32,337
MyrbetriqMirabegron38$23,647
VeltassaPatiromer Calcium Sorbitex11$20,738
Breo ElliptaFluticasone/Vilanterol33$17,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,044
FarxigaDapagliflozin Propanediol16$14,870
Tresiba Flextouch U-100Insulin Degludec16$9,851
Rosuvastatin Calcium367$7,789
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$7,411
LinzessLinaclotide13$6,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$67$122,366131 claims
PfizerEliquis$180$121,593160 claims
Novo NordiskOzempic$192$105,862106 claims
Lilly USA, LLCMounjaro$90$56,79352 claims
Johnson & JohnsonXarelto$11$43,26132 claims
GSKBreo Ellipta, Trelegy Ellipta$31$32,46748 claims
AstraZenecaFarxiga, Symbicort$33$17,45827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →